A Single-arm, Open-label, Multi-center Phase Ⅱa Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-IL-6R mAb Injection in the Treatment of Patients With Idiopathic Multicentric Castleman's Disease
Latest Information Update: 27 Jul 2023
At a glance
- Drugs Tocilizumab biobetter (Primary)
- Indications Giant lymph node hyperplasia
- Focus Adverse reactions
- Sponsors Beijing Weidejie Biotechnology
Most Recent Events
- 21 Jul 2023 Planned End Date changed from 1 Feb 2023 to 1 Dec 2024.
- 05 May 2022 New trial record